Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 20, 2004Annals of Neurology

Treatment of multiple sclerosis with an anti–interleukin‐2 receptor monoclonal antibody

View Full Paper
Ask AI
Bookmark
Share

Authors

JRJohn RoseBoston UniversityHWHilary E. WattAWAndrea T. WhiteUniversity of Utah

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Rose et al. (2004) studied this question.

synapsesocial.com/papers/6a993bfb4dca4b63f8f5b0f2https://doi.org/10.1002/ana.20287
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation1998 · 878 citations
  2. 2Multiple Sclerosis2000 · 2,909 citations
  3. 3Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial1999 · 260 citations
  4. 4Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β2004 · 315 citations